Ismpcanada.ca
Injectable haloperidol is also available in an
to confirmation bias, if it was mistakenly
Pharmacies, Ambulatory Clinics, and Hospitals
about alternative medications and any increases in
Institute for Safe Medication Practices Canada
A KEY PARTNER IN
immediate-release formulation (haloperidol USP, as
interpreted as meaning "lactate" (the salt present in
risk with use of unfamiliar or substitute products.
REPORT MEDICATION INCIDENTS
the lactate salt in a water-based formulation).3
the short-acting formulation).
• Consider how the name of the drug will appear in
Compared with haloperidol decanoate, the
the pharmacy computer system and on the product
Information System Vendors
immediate-release formulation has a much faster
label with the end user in mind. When expressing a
onset and shorter duration of action, which makes it
generic name, do not include the salt of the
• Ensure that sufficient character spaces are available
useful in the treatment of psychiatric emergencies.
chemical unless the medication is available in
in drug description fields and in pharmacy label
multiple salt formulations.5
formats to display the full generic name of all
In Canada, haloperidol is the only antipsychotic
With the growing number of marketed products
• Add alerts in pharmacy information systems,
drugs, including the salt, ester, or other complex,
Volume 14 • Issue 11 • December 18, 2014
available in both depot and immediate-release
with varied formulations available for selection,
electronic prescribing systems, and automated
when needed.
formulations. However, another antipsychotic,
prescription clarity is becoming increasingly
dispensing cabinets for injectable medications that
• Ensure that information systems support the use of
zuclopenthixol, is available in 2 different depot
are available in more than one formulation.
mixed case lettering in drug selection screens and
formulations (an acetate ester and a decanoate ester),
• Place labels on the shelves where these products are
label formats.
A Mix-up between Short- and Long-Acting Medications
with varied durations of action and dosing regimens.
• Consider using the entire name of depot
stored to alert practitioners of the availability of the
medications, including the salt, ester, or other
Administered by Injection: When Does the "Salt" Matter?
complex for medications available in more than
• Add depot injectable medications to the
one formulation, and state the desired strength; for
organization's list of medications requiring an
The variation in salts for drugs is clinically important
Errors involving mix ups between short- and
example, "haloperidol decanoate 100 mg/mL
independent double check before administration,
in certain situations, such as differentiation between
long-acting forms of IM medications can result in
long-acting injection (or depot)" instead of
where possible. For facilities and other practice
short-acting and depot formulations containing the
Medications may be formulated as salts or esters
5 mg/mL for injection. The nurse sent the
harm. A depot dose is typically much higher than a
"haloperidol LA".
settings that carry both short- and long-acting
same active medication. Mix-ups between
(collectively referred to as "salts"), usually to
prescription for "haloperidol LA 25 mg IM monthly"
dose of the same drug administered in a short-acting
dosage forms of a particular medication, the
formulations with different pharmacokinetic
improve the properties of the therapeutic moiety (e.g.,
to the pharmacy. The pharmacist dispensed
immediate-release form, because the former is
Front-Line Pharmacy and Nursing Staff
short-acting form should also require an
properties can lead to harm. Communicating drug
its stability, bioavailability, or duration of action). In
5 ampoules of the short-acting haloperidol lactate
designed to be slowly released into the body over an
independent double check. If a second practitioner
names with the end user in mind is becoming
most cases, the type of salt does not influence how
5 mg/mL to make up the 25 mg dose, which was
extended period. If the same high dose of a short-
• Contact the prescriber when the presence or
is not available to do the check, consider having the
increasingly important with the growing number of
the drug is therapeutically used. In some cases,
subsequently administered to the patient. Following
acting formulation is given by mistake, very high
absence of a medication name suffix (salt, ester, or
patient or a caregiver participate in the checking
drugs and the existence of varied formulations.
however, the particular salt significantly affects the
the injection, the patient's family noticed that he was
plasma levels of the drug may result, putting the
other complex) fails to align with the prescribed
process, in appropriate situations.1
Manufacturers, information system vendors, facilities,
drug's pharmacological properties. Depot
extremely sedated, was much less alert, and had a
patient at significant risk of overdose. As an example,
dose. For example, a prescription for "haloperidol
• Proactively alert staff about drug shortages and
pharmacies, and healthcare practitioners all have a
medications are one such group of drugs. These
"dazed" look, symptoms that lasted 3 days.
symptoms of haloperidol overdose include severe
100 mg" should be questioned, as the salt
provide anticipatory guidance about alternative
role in preventing incidents related to confusion
agents are typically formulated as various salts that
Fortunately, the patient recovered without any
extrapyramidal side effects, such as akathisia, acute
(formulation) is not specified and the dose appears
medications and any increases in risk with use of
between formulations of the same medication.
are used differently from their short-acting
dystonia, and parkinsonian symptoms.3 Also possible
to align with the depot formulation.4
unfamiliar or substitute products.
counterparts. ISMP Canada recently received a report
are increases in the risks of electrical disturbances of
• When multiple vials or ampoules or
• Provide education for staff in psychiatric clinics
of an incident in which a short-acting (immediate-
the heart, hypotension, hypokalemia, seizures,
larger-than-anticipated volumes are needed for a
and other settings where these products are used.
release) intramuscular (IM) form of an antipsychotic
respiratory depression, and coma.3
given dose, healthcare professionals should
Address the various formulations of antipsychotic
ISMP Canada gratefully acknowledges the following
was administered by injection to a patient instead of
Depot antipsychotics are commonly used in mental
question whether the correct product has been
medications and the differences between the
individuals for their expert review of this bulletin
the prescribed long-acting (depot) formulation. This
health care settings, for example, for maintenance
In this incident, in which short-acting haloperidol was
supplied. In the incident described in this bulletin,
formulations, including pharmacokinetic properties
(in alphabetical order):
bulletin is shared to increase awareness of the various
treatment of schizophrenia. Their main advantage is
given instead of the long-acting formulation, several
five 1 mL ampoules of haloperidol lactate 5 mg/mL
and therapeutic uses.
salt formulations of these drugs and to offer
low frequency of administration (every 1 to 4 weeks),
possible contributing factors were identified:
were needed for the prescribed dose of 25 mg; this
Lynne Duquette BScPhm, Clinical Pharmacist,
system-based changes to prevent these types of
which facilitates adherence with treatment.1
necessitated 2 IM injections to deliver the total
Manufacturers and Distributors
Waypoint Centre for Mental Health Care,
incidents from recurring.
• A drug shortage meant that the usual supply of
5 mL volume. In contrast, the decanoate
Penetanguishene, ON; James Karagianis MD
In most depot formulations of antipsychotics, the
haloperidol decanoate was unavailable in the clinic.
formulation for depot administration is available in
• Improve labelling on product packaging with the
FRCPC, Associate Professor of Psychiatry,
Medication Incident
active ingredient is available as the decanoate or
• Healthcare professionals were unfamiliar with the
concentrations of 50 mg/mL and 100 mg/mL, and
end user in mind. A new Good Label and Package
University of Toronto, Psychiatrist in Chief,
palmitate ester, which is dissolved in a vehicle such
differences between the 2 formulations and did not
the intended product would have required
Practices Guide is being developed by Health
Waypoint Centre for Mental Health Care,
An older patient had been receiving IM haloperidol
as sesame oil.2 These formulations are designed to be
understand that they are not interchangeable. Such
administration of less than 1 mL total volume.
Canada and ISMP Canada to provide guidance
Penatanguishene, ON; Nancy Kwast BSN RPN,
decanoate 25 mg every month for many years.
deposited via deep IM injection to provide prolonged
misconceptions may occur because for many
• If the viscosity of the medication seems unusual
regarding safe packaging and labelling of these
Community Nurse, Vancouver Adult Mental Health
Because of a medication shortage, this product was
therapeutic action as the drug is slowly absorbed
medications, the particular salt of the drug does not
compared with previous doses when aspirating
products. The guide will include recommendations
Intake, Vancouver Coastal Health, Vancouver, BC;
not available at the patient's ambulatory health
from its oily "depot" within the muscle into the
influence its properties and has no clinical
medication into the syringe, verify that the correct
about how to accurately communicate the drug
Helen McGee RN MN CPMHN(C), Advanced
centre, so a nurse called several pharmacies in the
bloodstream. Haloperidol decanoate is one such drug,
formulation is being prepared. Depot medications
name to practitioners.
Practice Nurse, Complex Mental Illness Program,
area in an attempt to procure the drug. Staff at one
and it is typically administered every 4 weeks.3
• The abbreviation "LA", which was used in the
are typically more viscous then their short-acting
• Proactively alert pharmacies and prescribers about
Centre for Addition and Mental Health, Toronto, ON.
pharmacy suggested using haloperidol lactate
prescription to mean "long-acting", might have led
drug shortages and provide anticipatory guidance
ISMP Canada Safety Bulletin
Injectable haloperidol is also available in an
to confirmation bias, if it was mistakenly
Pharmacies, Ambulatory Clinics, and Hospitals
about alternative medications and any increases in
immediate-release formulation (haloperidol USP, as
interpreted as meaning "lactate" (the salt present in
risk with use of unfamiliar or substitute products.
the lactate salt in a water-based formulation).3
the short-acting formulation).
• Consider how the name of the drug will appear in
Compared with haloperidol decanoate, the
the pharmacy computer system and on the product
Information System Vendors
immediate-release formulation has a much faster
label with the end user in mind. When expressing a
onset and shorter duration of action, which makes it
generic name, do not include the salt of the
• Ensure that sufficient character spaces are available
useful in the treatment of psychiatric emergencies.
chemical unless the medication is available in
in drug description fields and in pharmacy label
multiple salt formulations.5
formats to display the full generic name of all
In Canada, haloperidol is the only antipsychotic
With the growing number of marketed products
• Add alerts in pharmacy information systems,
drugs, including the salt, ester, or other complex,
available in both depot and immediate-release
with varied formulations available for selection,
electronic prescribing systems, and automated
when needed.
formulations. However, another antipsychotic,
prescription clarity is becoming increasingly
dispensing cabinets for injectable medications that
• Ensure that information systems support the use of
zuclopenthixol, is available in 2 different depot
are available in more than one formulation.
mixed case lettering in drug selection screens and
formulations (an acetate ester and a decanoate ester),
• Place labels on the shelves where these products are
label formats.
with varied durations of action and dosing regimens.
• Consider using the entire name of depot
stored to alert practitioners of the availability of the
medications, including the salt, ester, or other
complex for medications available in more than
• Add depot injectable medications to the
one formulation, and state the desired strength; for
organization's list of medications requiring an
The variation in salts for drugs is clinically important
Errors involving mix ups between short- and
example, "haloperidol decanoate 100 mg/mL
independent double check before administration,
in certain situations, such as differentiation between
long-acting forms of IM medications can result in
long-acting injection (or depot)" instead of
where possible. For facilities and other practice
short-acting and depot formulations containing the
Medications may be formulated as salts or esters
5 mg/mL for injection. The nurse sent the
harm. A depot dose is typically much higher than a
"haloperidol LA".
settings that carry both short- and long-acting
same active medication. Mix-ups between
(collectively referred to as "salts"), usually to
prescription for "haloperidol LA 25 mg IM monthly"
dose of the same drug administered in a short-acting
dosage forms of a particular medication, the
formulations with different pharmacokinetic
improve the properties of the therapeutic moiety (e.g.,
to the pharmacy. The pharmacist dispensed
immediate-release form, because the former is
Front-Line Pharmacy and Nursing Staff
short-acting form should also require an
properties can lead to harm. Communicating drug
its stability, bioavailability, or duration of action). In
5 ampoules of the short-acting haloperidol lactate
designed to be slowly released into the body over an
independent double check. If a second practitioner
names with the end user in mind is becoming
most cases, the type of salt does not influence how
5 mg/mL to make up the 25 mg dose, which was
extended period. If the same high dose of a short-
• Contact the prescriber when the presence or
is not available to do the check, consider having the
increasingly important with the growing number of
the drug is therapeutically used. In some cases,
subsequently administered to the patient. Following
acting formulation is given by mistake, very high
absence of a medication name suffix (salt, ester, or
patient or a caregiver participate in the checking
drugs and the existence of varied formulations.
however, the particular salt significantly affects the
the injection, the patient's family noticed that he was
plasma levels of the drug may result, putting the
other complex) fails to align with the prescribed
process, in appropriate situations.1
Manufacturers, information system vendors, facilities,
drug's pharmacological properties. Depot
extremely sedated, was much less alert, and had a
patient at significant risk of overdose. As an example,
dose. For example, a prescription for "haloperidol
• Proactively alert staff about drug shortages and
pharmacies, and healthcare practitioners all have a
medications are one such group of drugs. These
"dazed" look, symptoms that lasted 3 days.
symptoms of haloperidol overdose include severe
100 mg" should be questioned, as the salt
provide anticipatory guidance about alternative
role in preventing incidents related to confusion
agents are typically formulated as various salts that
Fortunately, the patient recovered without any
extrapyramidal side effects, such as akathisia, acute
(formulation) is not specified and the dose appears
medications and any increases in risk with use of
between formulations of the same medication.
are used differently from their short-acting
dystonia, and parkinsonian symptoms.3 Also possible
to align with the depot formulation.4
unfamiliar or substitute products.
counterparts. ISMP Canada recently received a report
are increases in the risks of electrical disturbances of
• When multiple vials or ampoules or
• Provide education for staff in psychiatric clinics
of an incident in which a short-acting (immediate-
the heart, hypotension, hypokalemia, seizures,
larger-than-anticipated volumes are needed for a
and other settings where these products are used.
release) intramuscular (IM) form of an antipsychotic
respiratory depression, and coma.3
given dose, healthcare professionals should
Address the various formulations of antipsychotic
ISMP Canada gratefully acknowledges the following
was administered by injection to a patient instead of
Depot antipsychotics are commonly used in mental
question whether the correct product has been
medications and the differences between the
individuals for their expert review of this bulletin
the prescribed long-acting (depot) formulation. This
health care settings, for example, for maintenance
In this incident, in which short-acting haloperidol was
supplied. In the incident described in this bulletin,
formulations, including pharmacokinetic properties
(in alphabetical order):
bulletin is shared to increase awareness of the various
treatment of schizophrenia. Their main advantage is
given instead of the long-acting formulation, several
five 1 mL ampoules of haloperidol lactate 5 mg/mL
and therapeutic uses.
salt formulations of these drugs and to offer
low frequency of administration (every 1 to 4 weeks),
possible contributing factors were identified:
were needed for the prescribed dose of 25 mg; this
Lynne Duquette BScPhm, Clinical Pharmacist,
system-based changes to prevent these types of
which facilitates adherence with treatment.1
necessitated 2 IM injections to deliver the total
Manufacturers and Distributors
Waypoint Centre for Mental Health Care,
incidents from recurring.
• A drug shortage meant that the usual supply of
5 mL volume. In contrast, the decanoate
Penetanguishene, ON; James Karagianis MD
In most depot formulations of antipsychotics, the
haloperidol decanoate was unavailable in the clinic.
formulation for depot administration is available in
• Improve labelling on product packaging with the
FRCPC, Associate Professor of Psychiatry,
Medication Incident
active ingredient is available as the decanoate or
• Healthcare professionals were unfamiliar with the
concentrations of 50 mg/mL and 100 mg/mL, and
end user in mind. A new Good Label and Package
University of Toronto, Psychiatrist in Chief,
palmitate ester, which is dissolved in a vehicle such
differences between the 2 formulations and did not
the intended product would have required
Practices Guide is being developed by Health
Waypoint Centre for Mental Health Care,
An older patient had been receiving IM haloperidol
as sesame oil.2 These formulations are designed to be
understand that they are not interchangeable. Such
administration of less than 1 mL total volume.
Canada and ISMP Canada to provide guidance
Penatanguishene, ON; Nancy Kwast BSN RPN,
decanoate 25 mg every month for many years.
deposited via deep IM injection to provide prolonged
misconceptions may occur because for many
• If the viscosity of the medication seems unusual
regarding safe packaging and labelling of these
Community Nurse, Vancouver Adult Mental Health
Because of a medication shortage, this product was
therapeutic action as the drug is slowly absorbed
medications, the particular salt of the drug does not
compared with previous doses when aspirating
products. The guide will include recommendations
Intake, Vancouver Coastal Health, Vancouver, BC;
not available at the patient's ambulatory health
from its oily "depot" within the muscle into the
influence its properties and has no clinical
medication into the syringe, verify that the correct
about how to accurately communicate the drug
Helen McGee RN MN CPMHN(C), Advanced
centre, so a nurse called several pharmacies in the
bloodstream. Haloperidol decanoate is one such drug,
formulation is being prepared. Depot medications
name to practitioners.
Practice Nurse, Complex Mental Illness Program,
area in an attempt to procure the drug. Staff at one
and it is typically administered every 4 weeks.3
• The abbreviation "LA", which was used in the
are typically more viscous then their short-acting
• Proactively alert pharmacies and prescribers about
Centre for Addition and Mental Health, Toronto, ON.
pharmacy suggested using haloperidol lactate
prescription to mean "long-acting", might have led
drug shortages and provide anticipatory guidance
ISMP Canada Safety Bulletin – Volume 14 • Issue 11 • December 18, 2014
Injectable haloperidol is also available in an
to confirmation bias, if it was mistakenly
Pharmacies, Ambulatory Clinics, and Hospitals
about alternative medications and any increases in
immediate-release formulation (haloperidol USP, as
interpreted as meaning "lactate" (the salt present in
risk with use of unfamiliar or substitute products.
the lactate salt in a water-based formulation).3
the short-acting formulation).
• Consider how the name of the drug will appear in
Compared with haloperidol decanoate, the
the pharmacy computer system and on the product
Information System Vendors
immediate-release formulation has a much faster
label with the end user in mind. When expressing a
onset and shorter duration of action, which makes it
generic name, do not include the salt of the
• Ensure that sufficient character spaces are available
useful in the treatment of psychiatric emergencies.
chemical unless the medication is available in
in drug description fields and in pharmacy label
multiple salt formulations.5
formats to display the full generic name of all
In Canada, haloperidol is the only antipsychotic
With the growing number of marketed products
• Add alerts in pharmacy information systems,
drugs, including the salt, ester, or other complex,
available in both depot and immediate-release
with varied formulations available for selection,
electronic prescribing systems, and automated
when needed.
formulations. However, another antipsychotic,
prescription clarity is becoming increasingly
dispensing cabinets for injectable medications that
• Ensure that information systems support the use of
zuclopenthixol, is available in 2 different depot
are available in more than one formulation.
mixed case lettering in drug selection screens and
formulations (an acetate ester and a decanoate ester),
• Place labels on the shelves where these products are
label formats.
with varied durations of action and dosing regimens.
• Consider using the entire name of depot
stored to alert practitioners of the availability of the
medications, including the salt, ester, or other
complex for medications available in more than
• Add depot injectable medications to the
one formulation, and state the desired strength; for
organization's list of medications requiring an
The variation in salts for drugs is clinically important
Errors involving mix ups between short- and
example, "haloperidol decanoate 100 mg/mL
independent double check before administration,
in certain situations, such as differentiation between
long-acting forms of IM medications can result in
long-acting injection (or depot)" instead of
where possible. For facilities and other practice
short-acting and depot formulations containing the
Medications may be formulated as salts or esters
5 mg/mL for injection. The nurse sent the
harm. A depot dose is typically much higher than a
"haloperidol LA".
settings that carry both short- and long-acting
same active medication. Mix-ups between
(collectively referred to as "salts"), usually to
prescription for "haloperidol LA 25 mg IM monthly"
dose of the same drug administered in a short-acting
dosage forms of a particular medication, the
formulations with different pharmacokinetic
improve the properties of the therapeutic moiety (e.g.,
to the pharmacy. The pharmacist dispensed
immediate-release form, because the former is
Front-Line Pharmacy and Nursing Staff
short-acting form should also require an
properties can lead to harm. Communicating drug
its stability, bioavailability, or duration of action). In
5 ampoules of the short-acting haloperidol lactate
designed to be slowly released into the body over an
independent double check. If a second practitioner
names with the end user in mind is becoming
most cases, the type of salt does not influence how
5 mg/mL to make up the 25 mg dose, which was
extended period. If the same high dose of a short-
• Contact the prescriber when the presence or
is not available to do the check, consider having the
increasingly important with the growing number of
the drug is therapeutically used. In some cases,
subsequently administered to the patient. Following
acting formulation is given by mistake, very high
absence of a medication name suffix (salt, ester, or
patient or a caregiver participate in the checking
drugs and the existence of varied formulations.
however, the particular salt significantly affects the
the injection, the patient's family noticed that he was
plasma levels of the drug may result, putting the
other complex) fails to align with the prescribed
process, in appropriate situations.1
Manufacturers, information system vendors, facilities,
drug's pharmacological properties. Depot
extremely sedated, was much less alert, and had a
patient at significant risk of overdose. As an example,
dose. For example, a prescription for "haloperidol
• Proactively alert staff about drug shortages and
pharmacies, and healthcare practitioners all have a
medications are one such group of drugs. These
"dazed" look, symptoms that lasted 3 days.
symptoms of haloperidol overdose include severe
100 mg" should be questioned, as the salt
provide anticipatory guidance about alternative
role in preventing incidents related to confusion
agents are typically formulated as various salts that
Fortunately, the patient recovered without any
extrapyramidal side effects, such as akathisia, acute
(formulation) is not specified and the dose appears
medications and any increases in risk with use of
between formulations of the same medication.
are used differently from their short-acting
dystonia, and parkinsonian symptoms.3 Also possible
to align with the depot formulation.4
unfamiliar or substitute products.
counterparts. ISMP Canada recently received a report
are increases in the risks of electrical disturbances of
• When multiple vials or ampoules or
• Provide education for staff in psychiatric clinics
of an incident in which a short-acting (immediate-
the heart, hypotension, hypokalemia, seizures,
larger-than-anticipated volumes are needed for a
and other settings where these products are used.
release) intramuscular (IM) form of an antipsychotic
respiratory depression, and coma.3
given dose, healthcare professionals should
Address the various formulations of antipsychotic
ISMP Canada gratefully acknowledges the following
was administered by injection to a patient instead of
Depot antipsychotics are commonly used in mental
question whether the correct product has been
medications and the differences between the
individuals for their expert review of this bulletin
the prescribed long-acting (depot) formulation. This
health care settings, for example, for maintenance
In this incident, in which short-acting haloperidol was
supplied. In the incident described in this bulletin,
formulations, including pharmacokinetic properties
(in alphabetical order):
bulletin is shared to increase awareness of the various
treatment of schizophrenia. Their main advantage is
given instead of the long-acting formulation, several
five 1 mL ampoules of haloperidol lactate 5 mg/mL
and therapeutic uses.
salt formulations of these drugs and to offer
low frequency of administration (every 1 to 4 weeks),
possible contributing factors were identified:
were needed for the prescribed dose of 25 mg; this
Lynne Duquette BScPhm, Clinical Pharmacist,
system-based changes to prevent these types of
which facilitates adherence with treatment.1
necessitated 2 IM injections to deliver the total
Manufacturers and Distributors
Waypoint Centre for Mental Health Care,
incidents from recurring.
• A drug shortage meant that the usual supply of
5 mL volume. In contrast, the decanoate
Penetanguishene, ON; James Karagianis MD
In most depot formulations of antipsychotics, the
haloperidol decanoate was unavailable in the clinic.
formulation for depot administration is available in
• Improve labelling on product packaging with the
FRCPC, Associate Professor of Psychiatry,
Medication Incident
active ingredient is available as the decanoate or
• Healthcare professionals were unfamiliar with the
concentrations of 50 mg/mL and 100 mg/mL, and
end user in mind. A new Good Label and Package
University of Toronto, Psychiatrist in Chief,
palmitate ester, which is dissolved in a vehicle such
differences between the 2 formulations and did not
the intended product would have required
Practices Guide is being developed by Health
Waypoint Centre for Mental Health Care,
An older patient had been receiving IM haloperidol
as sesame oil.2 These formulations are designed to be
understand that they are not interchangeable. Such
administration of less than 1 mL total volume.
Canada and ISMP Canada to provide guidance
Penatanguishene, ON; Nancy Kwast BSN RPN,
decanoate 25 mg every month for many years.
deposited via deep IM injection to provide prolonged
misconceptions may occur because for many
• If the viscosity of the medication seems unusual
regarding safe packaging and labelling of these
Community Nurse, Vancouver Adult Mental Health
Because of a medication shortage, this product was
therapeutic action as the drug is slowly absorbed
medications, the particular salt of the drug does not
compared with previous doses when aspirating
products. The guide will include recommendations
Intake, Vancouver Coastal Health, Vancouver, BC;
not available at the patient's ambulatory health
from its oily "depot" within the muscle into the
influence its properties and has no clinical
medication into the syringe, verify that the correct
about how to accurately communicate the drug
Helen McGee RN MN CPMHN(C), Advanced
centre, so a nurse called several pharmacies in the
bloodstream. Haloperidol decanoate is one such drug,
formulation is being prepared. Depot medications
name to practitioners.
Practice Nurse, Complex Mental Illness Program,
area in an attempt to procure the drug. Staff at one
and it is typically administered every 4 weeks.3
• The abbreviation "LA", which was used in the
are typically more viscous then their short-acting
• Proactively alert pharmacies and prescribers about
Centre for Addition and Mental Health, Toronto, ON.
pharmacy suggested using haloperidol lactate
prescription to mean "long-acting", might have led
drug shortages and provide anticipatory guidance
ISMP Canada Safety Bulletin – Volume 14 • Issue 11 • December 18, 2014
References
1. Feetam C, White J, editors. Guidance on the administration to adults of oil-based depot and other long-acting intramuscular
antipsychotic injections. 4th ed. Janssen-Cilag Ltd.; 2014 [cited 2014 Sep 28]. A
2. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatr Suppl
3. Haloperidol [product monograph]. In: e-CPS [database on Internet]. Ottawa (ON): Canadian Pharmacists Association; [cited 2014
Sep 28]. Available
4. Promoting the safe use of suffixes in prescription drug names: Council recommendations. National Coordinating Council for
Medication Error Reporting and Prevention; 2007 Dec 3 [cited 2014 Sep 28]. Available from:
5. Principles of designing a medication label for community and mail order pharmacy prescription packages. Horsham (PA): Institute for
Safe Medication Practices. 2010 [cited 2014 Nov 10]. Available from:
Invitation to Participate in a Delphi Method Survey on Medication
Safety Pictograms for Healthcare Workers
We would like to invite healthcare professionals to participate in the development of a set of
pictograms for medication safety. In this first phase, we are seeking assistance to identify the top
issues where the development of a pictogram might provide a visual aid and warning cue to help
prevent selected medication errors.
Ultimately, the use of a small set of medication safety pictograms could be considered when
labelling, dispensing, or administering medications.
This collaborative research project is being led by Dr. Regis Vaillancourt, Pharmacy Director at the
Children's Hospital of Eastern Ontario, and aims to involve pharmacists, pharmacy technicians,
nurses, physicians, and specialists such as anesthesiologists.
We have chosen to organize a Delphi consultation by email. The Delphi method is designed as a
group communication process which aims to achieve a convergence of opinions on a specific
real-world issue. The Delphi consists of three rounds, and each round should take approximately
10-15 minutes of your time to complete. After each round, a summary of the responses will be sent
to an expert group. The first Delphi round will include structured, as well as open-ended questions to
facilitate discussion. In addition, new topics provided by responses to the open-ended questions will
be disseminated to all Delphi participants in the second round.
Research ethics board approval was obtained for the study from the Children's Hospital of Eastern
Ontario (January 23, 2014). Your privacy and anonymity will be guaranteed and only the project
coordinators will have access to the raw information gathered, and to any personal information
ISMP Canada Safety Bulletin – Volume 14 • Issue 11 • December 18, 2014
This segment of the bulletin describes a recent SafeMedicationUse.ca publication from ISMP
Canada's consumer program.
December 2014 – Newsletter
Medication Appearance and Markings Support Safety
Consumers need to be familiar with the identification marks and general appearance of each of
their medications and any medications they administer to others.
SafeMedicationUse.ca received an incident report about a mix-up that occurred in a community
pharmacy between a consumer's prescriptions for 2 medications: the antibiotic ciprofloxacin (to be
used in treating a lung infection) and ranitidine (to be used on an as-needed basis for indigestion).
The error resulted in the ciprofloxacin tablets being placed in the vial labelled "ranitidine" and the
ranitidine tablets in the vial labelled "ciprofloxacin". For 6 days, the consumer took 3 ranitidine
tablets a day and did not take any ciprofloxacin. As a result, her infection was not treated properly
and lasted longer than expected. Fortunately, the consumer had some awareness of the markings
of the ranitidine tablets. This helped her to discover the error, which in turn helped her to
eventually get the correct treatment for her infection.
The SafeMedicationUse.ca newsletter advises consumers to take an active role in their health by
being familiar with the appearance (e.g., colour, shape, markings) of the medicines they take, by
checking their prescriptions before leaving the pharmacy, and by reviewing the details of new
prescriptions with the prescriber. Consumers are encouraged to read more about checking
To further support the consumer in this role, practitioners are encouraged to spend some time with
the consumer at the time of prescription pick-up, opening the vials, reviewing each product's
appearance, and informing the consumer of any changes to the medications' appearance.
For additional information about safe practices for consumers and practitioners, read the complete
ISMP Canada Safety Bulletin – Volume 14 • Issue 11 • December 18, 2014
Report Medication Incidents
(Including near misses)
The Canadian Medication Incident Reporting and Prevention
Phone: 1-866- 544-7672
System (CMIRPS) is a collaborative pan-Canadian program of Health Canada, the Canadian Institute for Health Information
ISMP Canada strives to ensure confidentiality
(CIHI), the Institute for Safe Medication Practices Canada
and security of information received, and
(ISMP Canada) and the Canadian Patient Safety Institute
respects the wishes of the reporter as to the
(CPSI). The goal of CMIRPS is to reduce and prevent harmful
level of detail to be included in publications.
medication incidents in Canada.
Stay Informed
To receive ISMP Canada Safety Bulletins
and Newsletters visit:
The Healthcare Insurance Reciprocal of Canada (HIROC)
provides support for the bulletin and is a member owned expert provider of professional and general liability coverage
This bulletin shares information about safe medication
and risk management support.
practices, is noncommercial, and is therefore exempt from Canadian anti-spam legislation.
Contact Us
Email: Phone: 1-866-544-7672
The Institute for Safe Medication Practices Canada (ISMP Canada) is an independent national not-for-profit
2014 Institute for Safe Medication Practices Canada.
organization committed to the advancement of medication
Permission is granted to subscribers to use material from
safety in all healthcare settings. ISMP Canada's mandate
the ISMP Canada Safety Bulletin for in-house newsletters
or other internal communications only. Reproduction by
recommendations for the prevention of harmful medication
any other process is prohibited without permission from
incidents, and facilitating quality improvement initiatives.
ISMP Canada in writing.
ISMP Canada Safety Bulletin – Volume 14 • Issue 11 • December 18, 2014
Source: http://www.ismpcanada.ca/download/safetyBulletins/2014/ISMPCSB2014-11_ShortLongActingMedications.pdf
LASER HAIR REMOVAL: SCIENTIFIC PRINCIPLES AND Christine C. Dierickx, MD Visiting Faculty Member Wellman Laboratories of Photomedicine Harvard Medical School The use of lasers for hair removal has been studied for a number of years. In this procedure,laser light is absorbed by melanin in the hair shaft, damaging the follicular epithelium. A clini-cal study evaluated the use of the LightSheer™ Diode Laser for hair removal. Of 92 patients,all had temporary hair loss and 89% had long-term hair loss. Regrowing hairs were shown tobe thinner and lighter than previously. Extensive clinical use of this high-power, pulsed diodelaser has resulted in recommendations for patient selection and proper use of the laser.Appropriate fluence settings have been shown to cause long-term hair loss without damagingthe epidermis, regardless of skin type.
This is an enhanced PDF from The Journal of Bone and Joint Surgery The PDF of the article you requested follows this cover page. What's New in Shoulder and Elbow Surgery Matthew L. Ramsey, Charles L. Getz and Bradford O. Parsons J Bone Joint Surg Am. 2008;90:677-687. doi:10.2106/JBJS.G.01544 This information is current as of November 20, 2009